Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD276-targeted CAR-T cells
- Development stage
- Unknown
- Lead developer
- The First Affiliated Hospital of Zhengzhou University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD276-targeted CAR-T cells (also known as B7-H3-targeted CAR-T cells) represent an investigational cellular immunotherapy platform consisting of T cells genetically engineered to express a chimeric antigen receptor (CAR) specific for CD276 (B7-H3). CD276 is an immune checkpoint molecule belonging to the B7 family that is frequently overexpressed across various solid tumors—including lung, esophageal, and colorectal cancers—while maintaining restricted expression in normal tissues. Upon binding to CD276 on the surface of malignant cells, these CAR-T cells undergo activation and proliferation, mediating targeted tumor cell lysis. This therapeutic approach is being evaluated in early-phase clinical trials, including a Phase I study sponsored by The First Affiliated Hospital of Zhengzhou University to assess safety and preliminary antitumor efficacy in patients with advanced solid tumors.
- Other names
- CD276 CAR-T cellsCD-276 CAR-T cellsCD 276 CAR-T cellsB7-H3-targeted CAR-T cellsB-7-H3-targeted CAR-T cellsB 7-H3-targeted CAR-T cellsB7-H3 CAR-T cellsB-7-H3 CAR-T cellsB 7-H3 CAR-T cells
02
Targets
B7-H3
Beyond the preview
Go deeper on CD276-targeted CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD276-targeted CAR-T cells.